Cassava Sciences, Inc. (SAVA)
|52 Week Range||2.28-117.54|
|1y Target Est||-|
|Debt / Equity||1.02%||Neutral|
Upgrades & Downgrades
Why Cassava Sciences Was Up 15% in May
Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval. ...
The Motley Fool
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. ...
Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately. ...
Zacks Investment Research
Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better
Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ. ...
Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease
- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time - ...
Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data
The only effective Alzheimer's treatment on the market is aricept, but its effect falls off after six months because it simply floods receptors. ...
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program ... ...
Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health
- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - ...
Buying Cassava Sciences Ahead Of July Data
The stock is off >70% from February high after going up 3x after the interim Alzheimer's data. Targeting $70 by the second interim data release in July (70% upside potential). ...
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease
- Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months – ...